Wetherby Asset Management Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 8.6% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,664 shares of the company’s stock after buying an additional 2,425 shares during the period. Wetherby Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $1,315,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in NVO. Mycio Wealth Partners LLC boosted its stake in Novo Nordisk A/S by 0.8% in the first quarter. Mycio Wealth Partners LLC now owns 20,280 shares of the company’s stock worth $695,000 after buying an additional 155 shares in the last quarter. Bessemer Group Inc. boosted its stake in Novo Nordisk A/S by 0.7% in the second quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock worth $1,431,000 after buying an additional 247 shares in the last quarter. Global X Management Co. LLC boosted its stake in Novo Nordisk A/S by 0.3% in the first quarter. Global X Management Co. LLC now owns 103,297 shares of the company’s stock worth $3,541,000 after buying an additional 283 shares in the last quarter. Headinvest LLC boosted its stake in Novo Nordisk A/S by 0.3% in the second quarter. Headinvest LLC now owns 110,025 shares of the company’s stock worth $4,719,000 after buying an additional 310 shares in the last quarter. Finally, Shamrock Asset Management LLC boosted its stake in Novo Nordisk A/S by 3.3% in the first quarter. Shamrock Asset Management LLC now owns 10,378 shares of the company’s stock worth $356,000 after buying an additional 334 shares in the last quarter. 6.40% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Novo Nordisk A/S (NYSE NVO) opened at 44.57 on Thursday. The firm has a market cap of $111.24 billion, a PE ratio of 18.33 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98. The firm’s 50-day moving average is $42.68 and its 200 day moving average is $38.69.
The company also recently declared a dividend, which will be paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st will be given a $0.336 dividend. The ex-dividend date of this dividend is Friday, August 18th. This is a boost from Novo Nordisk A/S’s previous dividend of $0.33. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 35.84%.
A number of research firms recently issued reports on NVO. Zacks Investment Research cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Finally, BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, June 15th. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Novo Nordisk A/S presently has a consensus rating of “Hold” and an average target price of $53.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.